KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Assets (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Assets for 8 consecutive years, with $512.7 million as the latest value for Q4 2025.

  • Quarterly Assets fell 4.94% to $512.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $512.7 million through Dec 2025, down 4.94% year-over-year, with the annual reading at $512.7 million for FY2025, 4.94% down from the prior year.
  • Assets hit $512.7 million in Q4 2025 for Adaptive Biotechnologies, up from $490.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.1 billion in Q1 2021 to a low of $490.6 million in Q3 2025.
  • Historically, Assets has averaged $733.8 million across 5 years, with a median of $741.1 million in 2023.
  • Biggest five-year swings in Assets: increased 22.54% in 2021 and later fell 23.5% in 2024.
  • Year by year, Assets stood at $923.3 million in 2021, then dropped by 7.23% to $856.6 million in 2022, then dropped by 22.82% to $661.1 million in 2023, then decreased by 18.42% to $539.4 million in 2024, then fell by 4.94% to $512.7 million in 2025.
  • Business Quant data shows Assets for ADPT at $512.7 million in Q4 2025, $490.6 million in Q3 2025, and $496.6 million in Q2 2025.